Abstract:Key PointsMost human cancers exhibit a high degree of intratumour heterogeneity that arises from heritable and stochastic genetic and epigenetic changes, as well as environmental variations within the tumour. Heterogeneous subpopulations that exist within close proximity and compete for limited resources can engage in complex interactions that affect tumorigenesis, disease progression and therapeutic outcomes.Phenotypic changes that arise from subclonal interactions in heterogeneous tumours were observed by cancer biologists very early on. However, as studies mostly focused on cell-autonomous oncogenes and tumour suppressors, investigations into clonal interactions went under the radar for almost three decades. With the increasing recognition of intratumour heterogeneity fuelled by advances in technology, dissecting the mechanistic basis of clonal interactions is now gaining more attention.In addition to the more traditional models that explore clonal interactions strictly from the competitive angle, newer studies are investigating cooperative interactions among subclones that could give rise to novel characteristics and that potentially increase the growth and progression of the tumour.In the absence of proper tools to directly study clonal interactions in patient samples, studies in D. melanogaster, rodents and xenograft systems (using both established cell lines and patient-derived cells) are providing us with mechanistic insights into interclonal crosstalk.Theoretical and mathematical modelling are being used to simulate clonal dynamics under variable circumstances. Although currently far from perfect, these in silico cancer models have already been useful for the design of optimized cancer therapies for the more effective eradication of tumours.Cooperation can be metabolically costly but evolution and survival are more efficient, especially in a changing environment, when diversity and heterogeneity are high. Insights from patient tumours have revealed the presence of multiple independent neoplastic driver subclones that could re-establish tumour heterogeneity after therapy and lead to disease relapse. Furthermore, there is increasing evidence of transient clonal cooperation between neoplastic and benign subclones, which can also lead to tumour recurrence.In order to tackle the ever-evolving populations of tumour cells more effectively and to devise more lasting cures in patients, we must use ecological approaches that take advantage of cooperative tumour-promoting interactions and strategically eliminate them instead of targeting each individual subpopulation.

The Genetic Evolution of Metastasis.

The evolution of tumor metastases during clonal expansion

Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution

An evolving cancer instigates clonally unrelated neighboring cells to form distant metastases

Single-cell Analysis Reveals Inter- and Intratumour Heterogeneity in Metastatic Breast Cancer

Cancer: Evolution Within a Lifetime

Isogenic Cell Lines Derived from Specific Organ Metastases Exhibit Divergent Cytogenomic Aberrations

Molecular Biology and Evolution of Cancer: From Discovery to Action

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Early and multiple origins of metastatic lineages within primary tumors

Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer

Genetic and non-genetic clonal diversity in cancer evolution

Targeting metastatic cancer

Molecular Insights into Tumour Metastasis: Tracing the Dominant Events

Cell Heterogeneity and Phenotypic Plasticity in Metastasis Formation: The Case of Colon Cancer

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma

The degenerative evolution from multicellularity to unicellularity during cancer

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations

Genomics Alterations of Metastatic and Primary Tissues Across 15 Cancer Types

The metabolism of cancer cells during metastasis

Tumorigenesis: it takes a village